...New Source of Translational Opportunities” ). New target for Senhwa synthetic lethal compound CX-5461 from Senhwa Biosciences Inc....
...pathway has been a major focus of research exploring synthetic lethality interactions beyond PARP-BRCA . Senhwa...
...Tuzman, Associate Editor CX-5461 American Society of Clinical Oncology ASCO Weizmann Institute of Science McMaster University Empirica Therapeutics Medical University of South Carolina Senhwa Biosciences Inc. Breast...

...6 μM, respectively). Next steps could include testing the compound in mouse models of RCC. Senhwa Biosciences Inc....

...big hit. TPEx has made a comeback, with seven IPOs in 2016-17 that culminated with Senhwa Biosciences Inc.’s...
...Inc., Zhubei, Taiwan Medigen Biotechnology Corp. (TPEx:3176), Taipei, Taiwan OBI Pharma Inc. (TPEx:4174), Taipei, Taiwan Senhwa Biosciences Inc....

...in December 2017. The trial was conducted in collaboration with the Peter MacCallum Cancer Centre. Senhwa...
...CX-5461 is an oral RNA polymerase I (Pol I) inhibitor and G-quadruplex (G4) DNA stabilizer. Senhwa Biosciences Inc....
...and antitumor activity Status: Phase I data Milestone: Start Phase II (2018) Mary Romeo CX-5461 American Society of Hematology ASH Senhwa Biosciences Inc. RNA...

...next year. JHL Biotech Inc. (TPEx-E:6540), Zhubei, Taiwan Jaime De Leon JHL1101 Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...

...multiple trials of the candidates next year. Jaime De Leon dornase alfa Herceptin JHL1101 Pulmozyme Rituxan rituximab Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...

...is developing BNZ-1 to treat large granular lymphocyte leukemia and cutaneous T cell lymphoma (CTCL). Senhwa Biosciences Inc....
...response (PR) at 24 weeks in 14 patients 3256 RNA polymerase I (Pol I) CX-5461 Senhwa Biosciences Inc....
...to treat leukemias Safety, HA-1 specific CD8+ T cell response in 9 healthy volunteers 1908 Senhwa Biosciences Inc....

...in the brain slice model, and in an orthotopic xenograft mouse model (see Distillery ). Senhwa Biosciences Inc....
...a druggable pathway controlling glioblastoma invasiveness." Cell Reports (2017) Winnie Pong, Staff Writer CX-4945 Curtana Pharmaceuticals Inc. Netherlands Cancer Institute Senhwa Biosciences Inc. Casein...

...therapies in animal models of GBM (see "Stopping the Invasion." BioCentury Innovations (Aug. 17, 2017)). Senhwa Biosciences Inc....

...NASDAQ:URGN) 5/3/17 $58.2 $155.6 $216.2 39% Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) 4/27/17 $63.6 $319.7 $211.4 -34% Senhwa Biosciences Inc....